Last reviewed · How we verify

propofol postconditioning

The Third Central Clinical College of Tianjin Medical University · FDA-approved active Small molecule

Propofol postconditioning is a cardioprotective strategy in which propofol is administered during the early reperfusion phase following ischemia to reduce myocardial injury and improve cardiac function.

Propofol postconditioning is a cardioprotective strategy in which propofol is administered during the early reperfusion phase following ischemia to reduce myocardial injury and improve cardiac function. Used for Myocardial ischemia-reperfusion injury during acute coronary syndrome, Cardioprotection during cardiac surgery with cardiopulmonary bypass.

At a glance

Generic namepropofol postconditioning
SponsorThe Third Central Clinical College of Tianjin Medical University
Drug classIntravenous anesthetic with cardioprotective properties
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Propofol, a commonly used intravenous anesthetic, has been studied as a postconditioning agent to mitigate ischemia-reperfusion injury in cardiac tissue. When administered at the onset of reperfusion after a period of ischemia, propofol appears to activate cardioprotective signaling pathways, reduce oxidative stress, and inhibit apoptosis, thereby preserving myocardial viability and function. This approach leverages propofol's antioxidant and anti-inflammatory properties to enhance recovery in acute coronary syndromes and cardiac surgery.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results